Related Experiment Video

Updated: Aug 2, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma

Pasi A Jänne1

  • 1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA. pjanne@partners.org

Annals of Medicine
|December 3, 2003
PubMed

Insights

Chemotherapy offers limited survival benefits for advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) inhibitors represent a new therapeutic strategy, with ongoing clinical trials exploring their efficacy alone and with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy remains the standard treatment for advanced non-small cell lung cancer (NSCLC).
  • Recent advancements in chemotherapy have yielded only marginal improvements in patient survival outcomes.
  • The discovery of molecular and genetic alterations in lung cancer has identified new therapeutic targets.

Purpose of the Study:

  • To review the pre-clinical rationale for targeting the epidermal growth factor receptor (EGFR) in NSCLC.
  • To summarize clinical studies investigating EGFR inhibitors in advanced NSCLC.
  • To evaluate the efficacy of EGFR inhibitors as monotherapy and in combination with chemotherapy.

Main Methods:

  • Review of pre-clinical data on EGFR and ErbB family signaling pathways.
  • Analysis of clinical trial data for EGFR inhibitors in advanced NSCLC.
  • Assessment of both antibody-based and small molecule EGFR inhibitors.

Main Results:

  • EGFR inhibitors show promise as targeted therapies for NSCLC.
  • Clinical development includes antibodies and small molecule inhibitors targeting EGFR.
  • Combination therapy with chemotherapy is under investigation.

Conclusions:

  • Targeting EGFR represents a rational therapeutic approach for advanced NSCLC.
  • Ongoing clinical trials are crucial for establishing the role of EGFR inhibitors.
  • Further research is needed to optimize treatment strategies involving EGFR inhibitors and chemotherapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...